It’s been a perplexing puzzle in the flu vaccine world — what’s going on with FluMist?

The Advisory Committee on Immunization Practices said last June that the live-attenuated vaccine, made by MedImmune (a division of AstraZeneca) should not be used this flu season because some US studies from three recent years suggested it offered poor or no protection in children aged 2 to 17.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • The easy answer would be rapidly mutating viral strains, or maybe Americans put too much other stuff up their noses. The problem has also probably led to some corporate agita as well. Reminds me when I worked for Lorex Pharmaceuticals, a JV between GD Searle and Synthelabo (now Sanofi). We were phase 3 of an international development program for what would have been the first non benzodiazepine anxiolytic. As the US monitor I was responsible for reviewed the lab results as they came across the printer. There was an unmistakable trend, with about 15% of the study subjects having significantly elevated liver enzymes along with pretty weak efficacy. When we informed our French JV partners who originally developed the drug they said “how come our drugs don’t work in America”. Ironically our next joint project was development of Ambien, which turned out to be, and still is a very popular drug. Development of the anxiolytic was eventually stopped due to the liver function problem.

Your daily dose of news in health and medicine

Privacy Policy